CAI
Caris Life SciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CAI
Caris Life Sciences, Inc.
A pioneer company in next-generation biotechnology and precision medicine based in Texas,USA
Healthcare Providers and Services
--
06/18/2025
NASDAQ Stock Exchange
1,769
12-31
Common stock
750 W. John Carpenter Freeway, Suite 800, Irving, TX 75039
--
Caris Life Sciences, Inc., was incorporated under the laws of the Cayman Islands in November 2011 and re-incorporated in Texas in July 2020, with headquarters in Irving, Texas. They are a leading, patient-centric, next-generation AI technology biotechnology company and precision medicine pioneer. They develop and commercialize innovative solutions to transform healthcare through the large-scale use of integrated molecular information and artificial intelligence/machine learning algorithms. Their entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology and serving the clinical, academic and biopharmaceutical markets.
Company Financials
EPS
CAI has released its 2025 Q3 earnings. EPS was reported at 0.08, versus the expected -0.14, beating expectations. The chart below visualizes how CAI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CAI has released its 2025 Q3 earnings report, with revenue of 216.83M, reflecting a YoY change of 113.38%, and net profit of 24.32M, showing a YoY change of 135.92%. The Sankey diagram below clearly presents CAI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
